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Abstract. Background: Acromegaly is an uncommon clinical disorder driven by high serum 
levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Over 99% of 
patients with acromegaly harbor a GH emitting pituitary adenoma. Pituitary tumors represent 
about 15% of essential intracranial neoplasms. Case presentation: A 38 years old woman, 
was referred to the H. Adam Malik central public hospital on December 15th, 2020, with 
chief complaints of enlarged fingers and toes. The patient complained that the patient's 
fingers and toes were getting bigger in the past 2 years. The brain MRI was performed showed 
intrasella spherical intensity lesions measuring ± 2.3x1.5x2 cm with the impression of 
macroadenoma. The patient later diagnosed with acromegaly due to pituitary macroadenoma. 
Therefore the patient was treated with administration of sandostatin injection, novorapid 6-
6-6 IU SC, then 0-0-12 IU SC, 3x1 salt capsules. The patient is also consulted to the 
neurosurgery department for surgical management plans and a consulted to the 
Ophthalmology Department. Conclusion: We report an instance of acromegaly suspected 
because of pituitary macroadenoma in a patient with unmistakable clinical highlights, with 
comprehensive management. 
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Abstrak: Latar belakang: Akromegali adalah kelainan klinis yang jarang akibat peninggian 
growth hormone (GH) serum dan insulin-like growth factor 1 (IGF-1). Lebih dari 99% 
pasien dengan akromegali memiliki adenoma hipofisis yang menstimulasi GH. Tumor 
hipofisis mewakili sekitar 15% dari neoplasma intrakranial esensial. Presentasi kasus: 
Seorang wanita berusia 38 tahun, dirujuk ke Rumah Sakit Umum Pusat H. Adam Malik pada 
tanggal 15 Desember 2020, dengan keluhan utama jari tangan dan kaki membesar. Pasien 
mengeluh jari tangan dan kaki pasien semakin membesar dalam 2 tahun terakhir. MRI otak 
yang dilakukan menunjukkan lesi intensitas sferis intrasella berukuran ± 2,3x1,5x2 cm 
dengan kesan makroadenoma. Pasien kemudian didiagnosis dengan akromegali akibat 
makroadenoma hipofisis. Oleh karena itu pasien dirawat dengan pemberian injeksi 
sandostatin, novorapid 6-6-6 IUSC, kemudian 0-0-12 IUSC, kapsul garam 3x1. Pasien juga 
akan dikonsultasikan ke departemen bedah saraf untuk rencana manajemen bedah dan 
dikonsultasikan ke departemen oftalmologi. Kesimpulan: Dilaporkan seorang pasien 
akromegali yang dicurigai karena makroadenoma hipofisis pada pasien dengan gambaran 
klinis yang jelas, dan dengan manajemen yang komprehensif. 
Kata kunci: Akromegali, Makroadenoma Hipofisis 
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1  Introduction 
Acromegaly is an uncommon clinical disorder driven by high serum levels of growth hormone 
(GH) and insulin-like growth factor 1 (IGF-1). The frequency of acromegaly is 3–4 cases for each 
million populace, and its commonness is assessed to go from 38 to 69 cases for every million [1]. 
Since a portion of the clinical profiles related to acromegaly are vague and the indications of the 
issue are treacherous, a few patients go undiscovered for quite a while after the beginning of 
starting signs and side effects [2]. Over 99% of patients with acromegaly harbor a GH emitting 
pituitary adenoma. Normal term from manifestations beginning to analysis is regularly 4–10 
years. Pituitary tumors represent about 15% of essential intracranial neoplasm. Given the basic 
area of the organ, extending tumors cause compressive side effects. At the point when tumors 
emerge in pituitary somatotroph cells, unusual emission of GH prompts the particular highlights 
of acromegaly. Practical pituitary adenomas are the most widely recognized reason for 
acromegaly, and the beginning of the infection is naturally steady, prompting a generous 
postponement in determination and treatment [3,4]. Early finding and brief treatment of this 
problem are indispensable as it conveys up to 72% expansion on the whole reason mortality when 
contrasted with everyone [5]. Allegedly, internists analyze 40% of acromegaly cases while the 
rest of analyzed by experts seen for specific side effects, for example, an ophthalmologist for 
visual aggravations [6]. We report an instance of acromegaly suspected because of pituitary 
macroadenoma in a patient with unmistakable clinical highlights.  
2 Case Illustration 
A 38 years old woman, was referred to the H. Adam Malik Hospital on December 15th, 2020, 
with chief complaints of enlarged fingers and toes (Fig, 1). The patient complained that the 
patient's fingers and toes were getting bigger in the past 2 years and the patient felt that it disturbed 
the patient's daily life so that the patient felt insecure about doing activities. Patients also realized 
that the face shape is getting more oval for about 2 years. The patient also noticed a widening of 
the forehead and thickening of the patient's nose and lips which arose with enlargement of the 
patient's fingers and toes. The patient also complained about the growing number of fine hairs on 
the patient's face, abdomen, and thighs, which the patient experienced for approximately 1 year 
and increased in these 6 months. The patient also complained of frequent sweating even though 
the patient was not doing strenuous activities or the weather was cold. 
 
 
Fig 2. Brain MRI 
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 03, No. 1, 2021                            9                                                          
Blurred eyes were also complained of by patients who were found in patients since 3 months ago 
and have become more severe since 1 month, blurred vision, especially in the outer field of view 
of the left and right eyes, the patient has difficulty reading small letters in newspapers or books 
and there is no change if the patient changes the distance between the newspapers or books that 
the patient reads. The patient has gone to an ophthalmologist and this complaint does not improve 
with the use of glasses. 
Headaches have also been experienced by the patient for 6 months and have worsened for this 
month, the headache is felt like throbbing and is felt evenly throughout the patient's head, 
sometimes it is also felt in certain areas of the patient's head, the patient's headaches are 
experienced and come on and off, then the headache is felt increasingly often and is felt 
continuously. Pain is felt reduced if she consumed anti-pain medication and then come back if 
you don't take pain medication, pain is felt so that sometimes it makes it difficult for the patient 
to do activities. 
The patient complained of getting smaller breasts for about 1 year. The history of the milk out of 
the patient's breast was denied by the patient. Menstrual disorders were also experienced by 
patients in the form of prolonged menstrual periods around 10-14 days and irregular menstruation. 
In 2016 the patient was diagnosed with a pituitary tumor and an operation was performed through 
the nose at an outside hospital but in the past 2 years, the patient has felt complaints reappearing. 
The patient denied a history of high blood pressure and diabetes. The patient had a history of 
consuming Cripsa 2.5 mg twice a day.  
From the examination, it was found that the patient body weight is 65 kg and height is 155 cm 
with a BMI of 27.1 Kg/m2 categorized as type 1 obesity. The vital sign examination was 
performed with a regular heart rate of 98 x/minit, blood pressure of 130/80 mmHg, the 
temperature of 36.7°C, and respiratory rate of 20x/minute. Physical examination showed 
prominent results as in facial appearances, with noticeable bigger nose and lips. A laboratory 
examination was performed on December 24th, 2020 consist of a complete blood count. Hb of 
15.3 gr/dL, Ht of 44 gr/dL, leukocytes of 5.130/mm3 and platelets of 207.000/mm3, testosterone 
level with 0.52 nmol/L,  fasting blood glucose level of 391 mg/dL, postprandial blood glucose 
level of 448 mg/dL and HbA1C 13.55. The brain MRI was performed on December 23 th 2020, 
showed intrasellar spherical intensity lesions measuring ±2,3x1,5x2 cm, lesions resulting in 
compression of the optic chiasma (Fig. 2). The patient was later diagnosed with acromegaly due 
to pituitary macroadenoma. Therefore the patient was treated with administration of Sandostatin 
injection, Novo rapid 6-6-6 IU SC, then 0-0-12 IU SC, 3x1 salt capsules. The patient is also 
consulted to the Neurosurgery Department for surgical management plans and a consulted to the 
Ophthalmology Department. 
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 03, No. 1, 2021                            10                                                          
3 Discussion 
Acromegaly is an uncommon issue with clinical signs that are essentially credited to the 
foundational impact of supported hypersecretion of GH. Entanglements related to this problem 
incorporate cardiovascular brokenness, respiratory trade-off, malignancies, metabolic confusions, 
skeletal anomalies, rheumatologic arthropathies, and neuropathies [5]. A few reports show a 
twofold to triple-expansion in mortality when contrasted and everybody, with cardiovascular 
occasions representing most of the mortality [6]. Other eminent reasons for death incorporate 
respiratory confusions and malignancies [7]. The increment in grimness and mortality related to 
acromegaly might be part of the way because of the guileful and reformist nature of the infection, 
which regularly prompts postponed analysis or potentially treatment [8]. Hence, it is basic that 
clinicians from all claims to fame keep a high file of doubt on patients giving explicit side effects 
who have trademark dysmorphic highlights of acromegaly.  
GH-emitting pituitary adenomas are the most well-known reason for acromegaly and as ongoing 
proof proposes, such tumors have a wide clinicopathologic variety [8]. This intertumoral 
heterogeneity clarifies why not all patients build up a quickly reformist aggregate and gives an 
understanding into the significant normal symptomatic deferral of eight years that is accounted 
for in numerous populace contemplates. Deferral in conclusion additionally likely clarifies why 
around 75% of somatotroph adenomas are identified as macroadenomas (adenoma > 10 mm) at 
the hour of analysis [9,10]. 
Current therapy alternatives incorporate transsphenoidal medical procedure, radiotherapy, or 
clinical treatment with dopamine agonists, somatostatin analogs, or GH receptors adversaries. 
Albeit skeletal and articular changes are perpetual, up to 70% of patients experience the goal of 
other foundational indications and metabolic difficulties [11]. 
Medical procedure, explicitly transsphenoidal adenectomy, seems, by all accounts, to be the pillar 
restorative methodology for most patients [4, 12]. Following finding and establishment of suitable 
treatment, it is additionally basic that a thorough workup of all organ frameworks engaged with 
this problem be sought after. The GH levels <2.5 ng/ml, youthful age, a more limited span of 
infection, and nonattendance of hypertension are indicators of longer endurance [7]. Untreated 
acromegaly is related to a huge dismalness and a decreased future. Cardiovascular illness is the 
main source of death [9]. 
4 Conclusion  
We report an instance of acromegaly suspected because of pituitary macroadenoma in a patient 
with unmistakable clinical highlights, with comprehensive management. 
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